A director at Destination Maternity Corp sold 291,766 shares at 0.384USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Destiny Pharma (DEST) is focused on developing innovative drugs with the potential to prevent or treat prevalent forms of drug resistant infection. Lead asset XF-73 has potential to be first to a $1.2bn core market. We think that its low propensity to trigger Antimicrobial Resistance (AMR) seen in testing to-date means the strong commercial rationale for XF-73 bucks the trend which has caused a steady retraction in Big Pharma antimicrobials pipelines. In FY18 DEST made progress on achieving its...
Destiny Pharma (DEST) is developing a pipeline of novel antimicrobials from its XF drug platform, to help combat highly prevalent and virulent bacteria. These include eight so far tested of those classed as urgent threats by the World Health Organisation and Centers for Disease Control (CDC), including MRSA (methicillin-resistant Staphylococcus aureus). DEST is progressing its lead program for Prevention of post-surgical Staph infection with intra nasal candidate XF-73 and is on track to commen...
Destiny Pharma (DEST) is developing a pipeline of novel antimicrobials from its XF drug platform, to help combat highly prevalent and virulent bacteria. These include eight so far tested of those classed as urgent threats by the World Health Organisation and Centers for Disease Control (CDC), including MRSA (methicillin-resistant Staphylococcus aureus). The unique mechanism of DEST’s new class of drug candidates could also help to overcome Anti-Microbial Resistance (AMR) that is a major limiti...
NEW YORK--(BUSINESS WIRE)-- Nathan G. Miller and Peter O’Malley (the “Investors”), collective holders of approximately 9% of the outstanding common stock of Destination Maternity Corporation (Nasdaq: DEST) (“Destination Maternity” or the “Company”), today released the following statement in regards to the recent report from Institutional Shareholder Services (ISS): “We are pleased that ISS agreed with our argument that the chronic underperformance at Destination Maternity is emblematic of a company not living up to its...
NEW YORK--(BUSINESS WIRE)-- Nathan G. Miller and Peter O’Malley (the “Investors”), collective holders of approximately 9% of the outstanding common stock of Destination Maternity Corporation (Nasdaq: DEST) (“Destination Maternity” or the “Company”), released the following letter to their fellow Destination Maternity shareholders, calling on them to vote the GOLD proxy card in favor of the Investors’ four highly qualified director nominees, Holly N. Alden, Christopher B. Morgan, Marla A. Ryan and Anne-Charlotte Windal (the “Nominees”) ...
NEW YORK--(BUSINESS WIRE)-- Please replace release due to two revisions. The final bullet point following the second paragraph has additional information. Also, the paragraph on Marla A. Ryan has been updated. The corrected release reads: INVESTOR GROUP NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES TO BOARD OF DESTINATION MATERNITY Nathan G. Miller and Peter O’Malley (the “Investors”), collective holders of 8.7% of the outstanding common stock of Destination Maternity Corporation (Nasdaq: DE...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Destination Maternity Corporation (Nasdaq: DEST) (“Destination Maternity” or the “Company”) relating to the proposed buyout of Destination Maternity by Orchestra Premaman S.A. Under the terms of the agreement, Destination Maternity shareholders are anticipated to receive 0.5150 Ame...
DALLAS--(BUSINESS WIRE)-- Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Destination Maternity Corp. (“Destination Maternity”) (NasdaqGS: DEST) concerning the sale to Orchestra Prémaman S.A. Under the terms of the agreement, Destination Maternity shareholders will only receive 0.5150 of an Orchestra share in the form of American Depository Shares for each share owned. The conside...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.